← Back to Screener
Silo Pharma, Inc. Common Stock (SILO)
Price$5.90
Value ScoreC
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-23.40%
Price vs S&P 500 (4W)-2.95%
VGM Score47.30
Market Capitalization$6.40M
All Metrics
Book Value / Share (Quarterly)$0.35
P/TBV (Annual)0.74x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)0.99%
Cash Flow / Share (Quarterly)$-0.27
Price vs S&P 500 (YTD)7.53%
Gross Margin (TTM)11.91%
Net Profit Margin (TTM)-6715.72%
EPS (TTM)$-0.50
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-0.50
Revenue Growth (5Y)12.51%
EPS (Annual)$-0.50
ROI (Annual)-67.05%
Gross Margin (Annual)38.56%
Net Profit Margin (5Y Avg)-3420.68%
Cash / Share (Quarterly)$0.39
Revenue Growth QoQ (YoY)0.00%
ROA (Last FY)-55.59%
Revenue Growth TTM (YoY)0.00%
EBITD / Share (TTM)$-0.45
ROE (5Y Avg)-41.80%
Operating Margin (TTM)-6726.32%
Cash Flow / Share (Annual)$-0.39
P/B Ratio1.13x
P/B Ratio (Quarterly)0.90x
Net Income / Employee (Annual)$-1,409,200
EV / Revenue (TTM)34.60x
Net Interest Coverage (TTM)-9.57x
ROA (TTM)-70.04%
EPS Incl Extra (Annual)$-0.50
Current Ratio (Annual)11.36x
Quick Ratio (Quarterly)8.90x
3-Month Avg Trading Volume0.23M
52-Week Price Return-38.54%
Revenue / Employee (TTM)$24,000
Tangible BV / Share (Quarterly)$0.34
P/S Ratio (Annual)88.74x
Asset Turnover (Annual)0.01x
52-Week High$15.15
Operating Margin (5Y Avg)-5390.48%
EPS Excl Extra (Annual)$-0.50
Tangible BV CAGR (5Y)45.19%
26-Week Price Return-15.47%
Quick Ratio (Annual)11.04x
13-Week Price Return12.38%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.65x
Enterprise Value$2.50M
Revenue / Share Growth (5Y)-25.45%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-8.86%
Revenue / Employee (Annual)$24,000
Inventory Turnover (Annual)0.67x
Pretax Margin (Annual)-5863.66%
Cash / Share (Annual)$0.54
3-Month Return Std Dev158.29%
Gross Margin (5Y Avg)84.47%
Net Income / Employee (TTM)$-1,614,500
ROE (Last FY)-67.05%
Net Interest Coverage (Annual)-9.83x
EPS Basic Excl Extra (Annual)$-0.50
P/FCF (TTM)13.33x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.50
Receivables Turnover (Annual)2.18x
ROI (TTM)-88.41%
P/S Ratio (TTM)88.72x
Pretax Margin (5Y Avg)-3321.37%
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$0.46
Price vs S&P 500 (52W)-62.91%
Year-to-Date Return15.69%
5-Day Price Return18.24%
EPS Normalized (Annual)$-0.50
ROA (5Y Avg)-31.81%
Net Profit Margin (Annual)-5863.66%
Month-to-Date Return-8.10%
EBITD / Share (Annual)$-0.52
Operating Margin (Annual)-5992.48%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-41.80%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.50
P/TBV (Quarterly)0.93x
P/B Ratio (Annual)0.72x
Inventory Turnover (TTM)0.00x
Pretax Margin (TTM)-6715.72%
Book Value / Share (Annual)$0.47
Price vs S&P 500 (13W)4.13%
Beta-33.61x
P/FCF (Annual)23.70x
Revenue / Share (TTM)$0.01
ROE (TTM)-88.41%
52-Week Low$3.31
vGradeC
gGradeC
mGradeC
vgmGradeC
Show chart for
Analyst Recommendations
Dec 2024
Jan 2025
Feb 2025
Mar 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SILOSilo Pharma, Inc. Common Stock | C | C | C | $5.90 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
SILO Pharma is a developmental stage biopharmaceutical company developing treatments for underserved psychiatric, pain, and neurological disorders using novel drug formulations and delivery systems. The company combines traditional and psychedelic-based therapeutic approaches, with its lead candidate, SPC-15, an intranasal treatment for PTSD and stress-induced anxiety.